(RTTNews) - INmune Bio, Inc. (INMB), on Tuesday presented baseline demographics and disease characteristics of participants in its MINDFuL Phase II clinical trial at the AD/PD 2025 Conference in ...

Patients with hereditary angioedema had lower attack rates, improved health-related quality of life and improved disease control with lanadelumab regardless of attack frequency at baseline, according ...